BICYCLE THERAPEUTICS PLC Cash Flow Statement
BCYC|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
BICYCLE THERAPEUTICS PLC used $250M in operating cash flow and negative free cash flow of $252M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.98 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$219.0M | -$169.0M | -$180.7M | -$51.0M | -$30.6M | -$21.8M | -$16.3M |
| Depreciation & Amortization | $6.4M | $7.2M | $6.5M | $1.3M | $960.0K | $712.0K | $332.0K |
| Operating Cash Flow | -$249.7M | -$164.7M | -$60.6M | -$17.8M | -$28.6M | -$26.1M | -$1.4M |
| Capital Expenditures | $2.4M | $1.2M | $2.9M | $1.2M | $1.6M | $1.2M | $1.1M |
| Free Cash Flow | -$252.0M | -$166.0M | -$63.6M | -$19.0M | -$30.2M | -$27.3M | -$2.5M |
| FCF Margin | -347.2% | -470.5% | -235.6% | -182.8% | -218.6% | -382.1% | -122.7% |